Overland Park, KS and Winston-Salem, NC — November 12, 2025 — Ronawk, the developer of the biological operating system (Bio-OS™), announced a strategic partnership agreement with the Amnion Foundation, a pioneering nonprofit dedicated to advancing research in perinatal stem cells. Through this collaboration, Amnion Foundation will leverage Ronawk’s platform to enhance the quality, scalability, and output of its birth tissue-derived cell lines.
Ronawk’s proprietary Bio-OS™ Platform Technology replicates the human biomechanical, signaling, and tissue environment thereby enabling cells, tissue, and biologics to thrive in conditions that mimic the human body. Together, the partnership aims to overcome scalability challenges while preserving native cell identity, potency, and functionality.
"The Amnion Foundation has built a unique and advanced process for proprietary cell lines with tremendous potential for regenerative medicine and therapeutic discovery," said Ronawk’s CEO A.J. Mellott, PhD. "This partnership will enable the expansion of these valuable cells while enhancing the biological relevance and consistency for Amnion’s customers and research partners."
Amnion’s Executive Director Anna Smith added, "Partnering with Ronawk enables us to accelerate the development of our cell lines using a physiologically relevant platform that preserves stemness and key biological properties. This marks a critical step toward unlocking the full therapeutic promise of our work."
The partnership marks a major advancement in efforts to overcome manufacturing and scalability challenges in the field of regenerative medicine. The ability to expand human tissue and cell lines In Similare (or ex vivo) opens new doors for applications in drug discovery, clinical translation, and biopharma development.
**About Ronawk**
Ronawk is building a biological operating system (Bio-OS™) that acts as a compass for mammalian biology. Legacy biomanufacturing technologies were designed for microbes like yeast or bacteria. They exhaust mammalian cells, making production inefficient and cost prohibitive. Bio-OS was purposely built from the ground up for mammalian cells, which are the very cells needed for therapies, biologics, and regenerative medicine.
How Bio-OS Works
· Clients define the outputs they need: stem cells, exosomes, or tissue components.
· Ronawk aligns key biological variables using our proprietary substrates and protocols.
· We then tune and customize outputs to customer specifications.
· The result is a standardized, enterprise-ready, and capital-efficient bio-manufacturing solution.
Instead of burning cells out, Ronawk’s Bio-OS cultivates them in environments that mimic the body. This yields healthier, more potent outputs at a fraction of the cost and footprint of current systems.
Ronawk Contact
Chief Business Development Officer
Scott Leigh
(913) 302-4792
Email for a press kit
**About Amnion**
The Amnion Foundation is a nonprofit organization providing birth tissue-derived cells and services to the scientific research community. Its core offerings include genetically stable stem cells isolated from amniotic fluid and placenta, known for their immunomodulatory, pro-angiogenic, and multi-lineage differentiation properties. The Amnion Foundation also provides various other birth-tissue derived cell types and offers customized isolation services.
Amnion Contact
Anna Gray Smith
Executive Director
(336) 955-2293
Find us online at amnionfoundation.org and LinkedIn.
